Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Orbis Medicines","sponsor":"Novo Holding","pharmaFlowCategory":"D","amount":"$28.1 million","upfrontCash":"Undisclosed","newsHeadline":"Orbis Medicines Launches with \u20ac26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable \u2018nCycles\u2019","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Orbis Medicines

    Menu

    Orbis Medicines

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Orbis Medicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’

              Details:

              The funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls nCycles, systematically designed by Orbis’ nGen1 platform to be orally bioavailable and membrane permeable.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Novo Holding

              Deal Size: $28.1 million Upfront Cash: Undisclosed

              Deal Type: Financing February 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY